All > Lenalidomide > Revlimid

Belantamab mafodotin for Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
MD Anderson Cancer Center, Houston, TXMultiple MyelomaBelantamab mafodotin - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new treatment for multiple myeloma that may help patients achieve remission.

Eligible Conditions
  • Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Lenalidomide
1
Lenalidomide
1
Lenalidomide

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year

Year 1
Conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Lenalidomide
1
Lenalidomide
1
Lenalidomide

Side Effects for

Phase 1 and Phase II: Event Free Survival and Overall Survival
44%Neutrophil count decreased
8%Infusion related reaction
8%Weakness
6%Fever
6%Fatigue
6%Platelet count decreased
6%Investigations - Other, specify
3%Infections and infestations - Other, specify
3%Hypokalemia
3%Left ventricular systolic dysfunction
3%Atrial fibrillation
3%Respiratory Failure
3%Myocardial infarction
3%sepsis
3%Chest pain
3%Pleural effusion
3%Atrial flutter
3%Cardiac arrest
3%Renal and urinary disorders - Other, specify
3%Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
3%Respiatory, thoracic and mediastinal disorders - Other, specify
3%confusion
3%Respiratory, thoracic and medicastinal disorders - Other, specify
3%Abdominal Pain
3%Nausea
3%Injury, poisoning and procedural complications - Other, specify
3%Acidosis
3%Cough
3%Encephalopathy
3%Aortic valve disease
This histogram enumerates side effects from a completed 2018 Phase 1 & 2 trial (NCT01060384) in the Phase 1 and Phase II: Event Free Survival and Overall Survival ARM group. Side effects include: Neutrophil count decreased with 44%, Infusion related reaction with 8%, Weakness with 8%, Fever with 6%, Fatigue with 6%.

Trial Design

2 Treatment Groups

Lenalidomide
1 of 2
Belantamab mafodotin
1 of 2

Experimental Treatment

94 Total Participants · 2 Treatment Groups

Primary Treatment: Belantamab mafodotin · No Placebo Group · Phase 2

Lenalidomide
Drug
Experimental Group · 1 Intervention: Lenalidomide · Intervention Types: Drug
Belantamab mafodotin
Drug
Experimental Group · 1 Intervention: Belantamab mafodotin · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Belantamab mafodotin
FDA approved
Lenalidomide
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,825 Previous Clinical Trials
1,792,477 Total Patients Enrolled
72 Trials studying Multiple Myeloma
5,630 Patients Enrolled for Multiple Myeloma
Qaiser BashirPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
63 Total Patients Enrolled
1 Trials studying Multiple Myeloma
60 Patients Enrolled for Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 11 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

What potential hazards are associated with Belantamab mafodotin?

"Taking into account the lack of evidence regarding efficacy, Belantamab mafodotin was assigned a safety score of 2." - Anonymous Online Contributor

Unverified Answer

What is the current participant count for this experiment?

"As of October 29th 2021, this trial is no longer enrolling patients. It was first posted on April 30th 2022 and has not been edited since then. Fortunately, 859 trials are available for those seeking treatment for multiple myeloma and a further 293 studies require participants taking Belantamab mafodotin." - Anonymous Online Contributor

Unverified Answer

What maladies is Belantamab mafodotin typically employed to treat?

"Belantamab mafodotin is widely used to combat chronic lymphocytic leukemia, but may also be deployed for those with amyloidosis or relapsed/refractory multiple myeloma who have received at least two prior systemic chemotherapy regimens." - Anonymous Online Contributor

Unverified Answer

Is enrollment still open for this clinical investigation?

"On clinicaltrials.gov, this medical experiment is not currently enrolling patients; the trial was first posted to the website on April 30th 2022 and lately updated October 29th 2021. Nonetheless, 1152 other studies are actively searching for participants presently." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top